康哲药业_亚太医疗企业日 2025— 核心要点_第三季度进展符合指引

Introducing new ophthalmology drugs to enhance competitive position: The company recently reached an agreement with Novartis to obtain China commercial rights of two anti-VEGF drugs -Lucentis (ranibizumab) and Beovu for the treatment 5 November 2025 | 1:12AM HKT Equity Research China Medical System Holdings (0867.HK): APAC Healthcare Corporate Day 2025 — Key Takeaways: 3Q progress on track with guidance Presenters: Susan Liu - Investor Relations Director of CMS; Yuyao Peng - Chief Financial Officer of Derma ...